O Shaughnessy Asset Management LLC Buys 228 Shares of United Therapeutics Co. (NASDAQ:UTHR)

O Shaughnessy Asset Management LLC grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,930 shares of the biotechnology company’s stock after buying an additional 228 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in United Therapeutics were worth $1,387,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the 4th quarter worth about $25,000. Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in United Therapeutics in the 4th quarter valued at approximately $131,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Down 4.8 %

Shares of UTHR stock opened at $292.46 on Friday. The company has a market cap of $13.13 billion, a price-to-earnings ratio of 12.84, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The firm has a 50 day moving average of $333.78 and a 200-day moving average of $354.46. United Therapeutics Co. has a 52 week low of $230.39 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the company earned $4.36 earnings per share. Analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $939,625.74. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock valued at $26,134,500 over the last three months. Corporate insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.